BTK inhibitor, ARQ 531, potently inhibits wild type and C481S mutant BTK and is superior to ibrutinib in TCL1 mouse model for CLL AKT inhibitor, ARQ 092, has potential to treat Sickle Cell Disease BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced that preclinical
BURLINGTON, Mass. --(BUSINESS WIRE)--Dec. 19, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 24, 2018 .
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to the Russell 2000 ® Index, a subset of the Russell 3000 ® Index, effective as of market closing on June 22, 2018 , at the conclusion of the annual Russell US Index
ArQule eligible to receive up to $336 million including upfront, regulatory and commercial milestone payments ArQule to host investor conference call including transaction details, AACR highlights and an update on clinical strategy April 18, 2018 at 9:00 A.M. ET BURLINGTON, Mass.
Parties to Focus on Immuno-Oncology Targets Collaboration Provides for Target Screening Through Clinical Development and Commercialization of Priority Compounds Agreement Leverages Applications of Beryllium Platforms to Validate Drug Targets and New Therapies WOBURN, Mass.
Planned interim analysis expected to occur early in the second quarter of 2016 BURLINGTON, Mass. and PARSIPPANY, N.J. , Dec. 10, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) and Daiichi Sankyo, Inc. today announced that the phase 3 METIV-HCC trial for tivantinib in second-line hepatocellular
WOBURN, Mass. & TOKYO --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET
DMC Recommends Discontinuation of Study for Futility No Unexpected Safety Findings from Interim Analysis WOBURN, Mass. & TOKYO --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3
WOBURN, Mass., Oct 12, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology.
These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.